PATENT COOPERATION TREAT.

From the INTERNATIONAL SEARCHING AUTHORITY

	the same of the sa
To: Venable Attn. Genieser, Lazs H. P.O. Box 34385 Washington, DC 20043-9998 ETATS-UNIS D'AMERIQUE	NOTIFICATION OF THANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION
	(PCT Rule 44.1)
	Date of mailing (day/month/year) 08/04/2009
Applicant's or agent's file reference	
58086-265753	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No.	International filing date
PCT/US2008/013319	(day/month/year) 03/12/2008
Applicant	
PARHAMI, FARHAD	
Authority have been established and are transmitted herewit	report and the written opinion of the International Searching th.
Filing of amendments and statement under Article 19:	

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46): When? The time limit for filling such amendments is normally two months from the date of transmittal of the International Search Report,

Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes 1211 Geneva 20, Switzerland, Fascimile No.: (41-22) 338,82,70

For more detailed instructions, see the notes on the accompanying sheet.

The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.

With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4 Reminders

Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site. Astical 19

> 2 MONTH REMINDER 1 MONTH REMINDER

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Riiswilk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.

Name and mailing address of the International Searching Authority

Authorized officer Saskia Stark

2 WEEK REMINDER

3 DAY REMINDER

8/09

6000

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Pattent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the POT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS LINDER ARTICLE 19

The applicant has, after having received the international search report and the written opinion of the international Searching Authority, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims,description and drawings) may be amended during the international prefininging examination procedure, there is usually no need to file amendments of the claims under Article 19 experiments on the applicant learning the latter to be published for the purposes of provisional protection is has another protection is available in some States only (see PCT Applicant's Guide, Volume IA, Anneyse B1 and B2), provisional protection is available in some States only (see PCT Applicant's Guide, Volume IA, Anneyse B1 and B2).

The attention of the applicant is drawn to the fact that amendments to the claims under Article 19 are not allowed where the International Searching Authority has declared, under Article 17(2), that no international search report would be established (see *PCT Applicant's Guide*. Volume I/A. paragraph 296).

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the International phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry Into the national phase, all parts of the International application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time finit exprise later, it should be noted, nowever, that the amendments will be considered as having been received on time if they are received by the international Bureau after the expiration of the applicable time limit but before the completion of the technical or necessarions for international publication (Pulse 46 high.)

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French. the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped, whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 22, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 38 undanaged, new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims;
 "Cialms 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added," or "Cialms 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application. Is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filled on a separate sheet and must be lidentified as such by a heading, preferably by using the words "Statement under Article 19f1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted. He applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and or any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For turber information, see the Notes to the demand form (PCT/IPEAVIOT).

If a demand for international preliminary examination is made, the written opinion of the international Searching Authority will, except in cardial cases where the International Preliminary Examining Authority did not act as international Searching Authority and where it has notified the International Bureau under Rule 66. 1.0s(b), be considered to be a written opinion of the International Preliminary Examining Authority in right be the written made, the applicant may submit to the International Preliminary Examining Authority in right be the written opinion forgether than the Authority of the Authority of the Control of the Control of the Authority of the Authority of the Control of the Authority of the Author

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide, Volume II

PATENT COOPERATION TREAT.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220
58086-265753	ACTION as well	as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US2008/013319	03/12/2008	03/12/2007
Applicant		
PARHAMI, FARHAD		
This International search report has been according to Article 18. A copy is being to	prepared by this International Searching Author	rity and is transmitted to the applicant
This international search report consists of	of a total of 4 sheets.	
_	a copy of each prior art document cited in this	report.
Basis of the report		, , , , , , , , , , , , , , , , , , ,
_	international search was carried out on the bas	sis of:
	application in the language in which it was filed	
	e International application into rnished for the purposes of International searci	, which is the language n (Rules 12.3(a) and 23.1(b))
b. This international search authorized by or notified to	report has been established taking into accoun o this Authority under Rule 91 (Rule 43.6 <i>bis</i> (a)	t the rectification of an obvious mistake).
c. With regard to any nucle	otide and/or amino acid sequence disclosed	in the International application, see Box No. I.
2. Certain claims were fou	nd unsearchable (See Box No. II)	
3. Unity of invention is lac	king (see Box No III)	
4. With regard to the title,		
X the text is approved as su	bmitted by the applicant	
the text has been e stablis	hed by this Authority to read as follows:	
- 1100		
5. With regard to the abstract,	to the discount of the second	
X the text is approved as su		to the second of
may, within one month fro	hed, according to Rule 38.2(b), by this Authori m the date of mailing of this international sear	ch report, submit comments to this Authority
With regard to the drawings,		
	ublished with the abstract is Figure No. 10	
X as suggested by	-	
	s Authority, because the applicant failed to sug	gest a figure
_	s Authority, because this figure better characte	
	e published with the abstract	

INT PNATIONAL SEARCH REPORT

ternational application No

PCT/US2008/013319 A61P19/10

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/575 A61P19/08 A61P3/04 A61P17/14

A61P19/02

A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Helevant to claim No.
х	WO 2007/098281 A (UNIV CALIFORNIA [US]; PARHAMI FARHAD [US]; JUNG MICHAEL E [US]; DWYER) 30 August 2007 (2007-08-30) cited in the application abstract; claims 1-57; figures 9a,9b	1-40
X	WO 2007/028101 A (UNIV CALIFORNIA [US]; PARHAMI FARHAD [US]) 8 March 2007 (2007-03-08) cited in the application abstract; claims 1-48	1-40
Х	WO 2005/020928 A (UNIV CALIFORNIA [US]; PARHAMI FARHAD [US]) 10 March 2005 (2005-03-10) cited in the application abstract; claims 1-51	1-9, 12-40

X	Further documents are listed in the	continuation of Box C.
---	-------------------------------------	------------------------

* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance

- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search

"&" document member of the same patent family Date of mailing of the international search report

1 April 2009

08/04/2009

Authorized officer

X See patent family annex.

T later document published after the international filling date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the

"X" document of particular relevance; the claimed invention

cannot be considered novel or cannot be considered to

involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention

cannot be considered to involve an inventive step when the document is combined with one or more other such docu-

ments, such combination being obvious to a person skilled in the art.

Name and mailing address of the ISA/

1

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040,

Madalinska K

INT 'RNATIONAL SEARCH REPORT

nternational application No

Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	PCT/US2008/013319
gory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N
	AGHALOO T ET AL: "Oxysterols enhance osteoblast differentiation in vitro and bone healing in vivo." JOURNAL OF BONE AND MINERAL RESEARCH, vol. 20, no. 9, Suppl. 1, September 2005 (2005-09), page S361, XP009114658 & ZTH ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-BONE-AND-MINERAL-RESE ARCH; NASHVILLE, TN, USA; SEPTEMBER 23 -27, 2005 ISSN: 0884-0431 abstract	1-9, 12-40
	KIM WOO-KYUN ET AL: "20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism." JOURNAL OF BONE AND MINERAL RESEARCH, vol. 22, no. 11, November 2007 (2007-11), pages 1711-1719, XP009114749 ISSN: 0884-0431 abstract	1-9, 12-40
X	WO 2008/115469 A (UNIV CALIFORNIA [US]; PARHAMI FARHAD [US]) 25 September 2008 (2008-09-25) cited in the application abstract; claims 1-44; compounds OXY20,22,26,27,28,34,36,38-42,48-49	1-6,10, 13-25, 28-40

INT "RNATIONAL SEARCH REPORT

information on patent family members

nternational application No
PCT/US2008/013319

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2007098281	A	30-08-2007	AU CA EP	2007217366 2643732 1993558	A1	30-08-2007 30-08-2007 26-11-2008
WO 2007028101	A	08-03-2007	AU CA EP	2006284650 2621157 1931353	A1	08-03-2007 08-03-2007 18-06-2008
WO 2005020928	Α	10-03-2005	NONE			
WO 2008115469	Α	25-09-2008	NONE			

PATENT COOPERATION 1 SATY

From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (dav/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/US2008/013319 03.12.2008 03.12.2007 International Patent Classification (IPC) or both national classification and IPC INV. A61K31/575 A61P19/08 A61P19/02 A61P19/10 A61P9/10 A61P3/04 A61P17/14 Applicant PARHAMI, FARHAD 1 This opinion contains indications relating to the following items: ☑ Box No. I Basis of the opinion Box No. II Priority ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☐ Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis,1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited ☐ Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66,1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. Mri Hen Opinion 2 MONTH REMINDER For further options, see Form PCT/ISA/220. 1 MONTH REMINDER For further details, see notes to Form PCT/ISA/220. 2 WEEK REMINDER 6/24/09 4/5/0 3 DAY REMINDER ACTION DUE AND DATE 321 Name and mailing address of the ISA: Date of completion of Authorized Officer

this opinion

PCT/ISA/210

Madalinska, K

see form

European Patent Office

D-80298 Munich

International application No. PCT/US2008/013319

	Box	k No). I	Basis of the opinion
1.	Wit	h reç	gard	to the language, this opinion has been established on the basis of:
	\boxtimes	the	inte	rnational application in the language in which it was filed
				lation of the international application into , which is the language of a translation furnished for the es of international search (Rules 12.3(a) and 23.1 (b)).
2.	<u> </u>			inion has been established taking into account the rectification of an obvious mistake authorized otified to this Authority under Rule 91 (Rule 43bis.1(a))
3.	Wit	h reg	gard ary t	to any nucleotide and/or amino acid sequence disclosed in the international application and othe claimed invention, this opinion has been established on the basis of:
	a. ty	уре	of m	aterial:
	[_	a se	equence listing
	[tabl	e(s) related to the sequence listing
	b. fo	orma	at of	material:
	[on p	paper
	[in e	lectronic form
	c. ti	me (of fil	ing/furnishing:
			con	tained in the international application as filed.
	[filed	together with the international application in electronic form.
	[furn	ished subsequently to this Authority for the purposes of search.
4.		has	s bee	ion, in the case that more than one version or copy of a sequence listing andor table relating thereto en filed or furnished, the required statements that the information in the subsequent or additional is intelligent to that in the application as filed or does not go beyond the application as filed, as intelligent furnished.
5.	Add	lition	nal c	omments:
	Вох	(No	ı. II	Priority
1.	⊠	doe	es no	idity of the priority claim has not been considered because the International Searching Authority to have in its possession a copy of the earlier application whose priority has been claimed or, where d. a translation of that earlier application. This opinion has nevertheless been established on the

assumption that the relevant date (Rules 43bis.1 and 64.1) is the claimed priority date.

This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43b/s.1 and 64.1). Thus for the purposes of this opinion, the international filling date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2008/013319

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1-40

1. Statement

Novelty (N)

Yes: Claims No: Claims

Inventive step (IS)

Yes: Claims

No: Claims <u>1-40</u>

Industrial applicability (IA)

Yes: Claims <u>1-40</u>

No: Claims

2. Citations and explanations

see separate sheet

Box No. VI Certain documents cited

1. Certain published documents (Rules 43bis.1 and 70.10)

and / or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

- 1. Reference is made to the following documents:
 - D1: WO 2007/098281 A:
 - D2: WO 2007/028101 A;
 - D3: WO 2005/020928 A;
 - D4: Journal of Bone and Mineral Research 2005, 20, S361 XP009114658;
- D5: WO 2008/115469.
- The relevant passages are those indicated in the search report, unless otherwise specified.

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- The patentability of claims 1-40 is inter alia dependent upon their formulation as well as upon national and regional laws and no criteria is provided in this field by the PCT. Their assessment will be carried out based on the alleged effects of the compounds of formula (I) searched in the International Search Report.
- 4. None of the documents in the prior art discloses the compound of formula (I) for use in the treatment of bone disorder, osteoporosis, osteoporitis, osteoarthritis, a bone fracture, obesity, xanthoma, cardiovascular disorder, arteriosclerosis, myocardial infarction, peripheral vascular disease, stroke and/or alopecia.

D1 discloses the treatment of bone and vascular disorders or alopecia by using a compound of formula (I), which are excluded by means of disclaimer from the claimed subject-matter.

D2-D4 disclose treatment of bone disorders by using oxysterols including 20hydroxycholesterol, that is excluded by means of disclaimer from the claimed subject-matter.

Accordingly, D1-D4 are not prejudicial to novelty of the claimed subject-matter and therefore, claims 1-40 are considered as meeting the requirements of Article 33(2) PCT.

- However, the Applicant should bear in mind the content of D5 (cited under section VI) which could be held prejudicial to the novelty of claims 1-6, 10, 13-25, 28-40 during Regional or National examination phase(s).
- The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claims 1-40 does not involve an inventive step in the sense of Article 33(3) PCT.

D1 relating to the oxysterols of formula (I) as the inhibitors of Hedgehog pathway for use in the treatment of bone and vascular disorders or alopecia is considered as the closest prior art for the subject-matter of claims 1-40.

D2-D4 relating the treatment of bone disorders such as osteoporosis by using 17-substituted oxysterols including 20-hydroxycholesterol can also be regarded as the closest prior art for the subject-matter of claims 1-9 and 12-40.

The compounds of D1-D4 which are excluded by the proviso of claims 1 and 21 appear to be only, if any, minor modifications of the claimed derivatives.

Therefore, such a minor modification must be regarded as obvious solution to the provision of alternative compounds for the treatment of the bone and vascular disease or alopecia of the present application.

Accordingly, an inventive step cannot be acknowledged in the absence of evidence showing that substantially all the claimed compounds have unexpected property or improved activity with respect to the structurally closest prior art compounds of D1-D4.

Re Item VI

Certain documents cited

D5 is cited under Rules 64.3 and 70.10 PCT.

Re Item VIII

Certain observations on the international application

8. The present independent claims 1, 13 and 21 encompass a composition/compound defined by their desired function ("...wherein the compounds induces a biological response...", "...an amount sufficient to induce..."), contrary to the requirements of clarity of Article 6 PCT. The claims attempt to define the subject-matter in terms of the result to be achieved without providing the technical features necessary for achieving this result. Such a "result-to-be-achieved" type definition does not allow the scope of the claim to be ascertained.

The subject-matter for which protection is desired should be defined in concrete terms, i.e. in terms of how the aforementioned result is to be achieved and in terms clearly defining the instructions enabling the person skilled in the art to reproduce in practice the invention without undue burden and without inventive skills.

- 9. Independent claim 14 does not meet the requirements of Article 6 PCT for the following reasons. The therapeutic application of the products is functionally defined by a mechanism of action (i.e. by their capability of modulating a hedgehog pathway response, a Wnet inhibitory Factor-1 pathway), which does not allow any practical application in the form of a defined, real treatment of a pathological condition (disease).
- 10. The number of independent claims is unreasonable (Rule 6.1(a) PCT).

Possible steps after receipt of the international search report (ISR) and written opinion of the International Searching Authority (WO-ISA)

General information.

For all international applications filed on or after 01/01/2004 the competent ISA will establish an ISR. It is accompanied by the WO-ISA. Unlike the former written opinion of the IPEA (Rule 66.2 PCT), the WO-ISA is not meant to be responded to, but to be taken into consideration for further procedural steps. This document explains about the possibilities.

under Art. 19 PCT

Amending claims Within 2 months after the date of mailing of the ISR and the WO-ISA the applicant may file amended claims under Art. 19 PCT directly with the International Bureau of WIPO. The PCT reform of 2004 did not change this procedure. For further information please see Rule 46 PCT as well as form PCT/ISA/220 and the corresponding Notes to form PCT/ISA/220.

Filing a demand for international preliminary examination

In principle, the WO-ISA will be considered as the written opinion of the IPEA. This should, in many cases, make it unnecessary to file a demand for international preliminary examination. If the applicant nevertheless wishes to file a demand this must be done before expiry of 3 months after the date of mailing of the ISR/WO-ISA or 22 months after priority date, whichever expires later (Rule 54bis PCT). Amendments under Art. 34 PCT can be filed with the IPEA as before, normally at the same time as filing the demand (Rule 66.1 (b) PCT).

If a demand for international preliminary examination is filed and no comments/amendments have been received the WO-ISA will be transformed by the IPEA into an IPRP (International Preliminary Report on Patentability) which would merely reflect the content of the WO-ISA. The demand can still be withdrawn (Art. 37 PCT).

Filing informal comments.

After receipt of the ISR/WO-ISA the applicant may file informal comments on the WO-ISA directly with the International Bureau of WIPO. These will be communicated to the designated Offices together with the IPRP (International Preliminary Report on Patentability) at 30 months from the priority date. Please also refer to the next box.

End of the international phase

At the end of the international phase the International Bureau of WIPO will transform the WO-ISA or, if a demand was filed, the written opinion of the IPEA into the IPRP, which will then be transmitted together with possible informal comments to the designated Offices. The IPRP replaces the former IPER (international preliminary examination report).

Relevant PCT Rules and more inform ation

Rule 43 PCT, Rule 43bis PCT, Rule 44 PCT, Rule 44bis PCT, PCT Newsletter 12/2003, OJ 11/2003, OJ 12/2003

Bitte beachten Sie, dass angeführte Nichtpatentliteratur (wie z.B. wissenschaftliche oder technische Dokumente) je nach geltendem Recht dem Urheberrechtsschutz und/oder anderen Schutzarten für schriftliche Werke unterliegen könnte. Die Vervielfältigung urheberrechtlich geschützter Texte, ihre Verwendung in anderen elektronischen oder gedruckten Publikationen und ihre Weitergabe an Dritte ist ohne ausdrückliche Zustimmung des Rechtsinhabers nicht gestattet.

Veuillez noter que les ouvrages de la littérature non-brevets qui sont cités, par exemple les documents scientifiques ou techniques, etc., peuvent être protégés par des droits d'auteur et/ou toute autre protection des écrits prévue par les législations applicables. Les textes ainsi protégés ne peuvent être reproduits ni utilisés dans d'autres publications électroniques ou imprimées, ni rediffusés sans l'autorisation expresse du titulaire du droit d'auteur.

Please be aware that cited works of non-patent literature such as scientific or technical documents or the like may be subject to copyright protection and/or any other protection of written works as appropriate based on applicable laws. Copyrighted texts may not be copied or used in other electronic or printed publications or re-distributed without the express permission of the copyright holder.